Alnylam Pharmaceuticals
ALNY
#1145
Rank
โ‚ฌ18.15 B
Marketcap
135,55ย โ‚ฌ
Share price
-3.21%
Change (1 day)
-64.57%
Change (1 year)
Alnylam Pharmaceuticals Inc. is a biopharmaceutical company focused on the R&D and commercialization of RNA interference (RNAi) therapeutics for genetically defined diseases.

EPS for Alnylam Pharmaceuticals (ALNY)

EPS in 2023 (TTM): -3,77ย โ‚ฌ

According to Alnylam Pharmaceuticals 's latest financial reports the company's current EPS (TTM) is 17,71ย โ‚ฌ. In 2022 the company made an earnings per share (EPS) of -8,31ย โ‚ฌ a decrease over its 2021 EPS that were of -6,44ย โ‚ฌ.

EPS history for Alnylam Pharmaceuticals from 2003 to 2023

Annual EPS

Year EPS Change
2023 (TTM)-3,77ย โ‚ฌ-54.68%
2022-8,31ย โ‚ฌ29.03%
2021-6,44ย โ‚ฌ-3.36%
2020-6,66ย โ‚ฌ-8.48%
2019-7,28ย โ‚ฌ7.67%
2018-6,76ย โ‚ฌ39.74%
2017-4,84ย โ‚ฌ12.94%
2016-4,28ย โ‚ฌ38.84%
2015-3,08ย โ‚ฌ-32.88%
2014-4,60ย โ‚ฌ259.44%
2013-1,28ย โ‚ฌ-31.25%
2012-1,86ย โ‚ฌ52.94%
2011-1,22ย โ‚ฌ30.77%
2010-0,93ย โ‚ฌ-8.77%
2009-1,02ย โ‚ฌ78.13%
2008-0,57ย โ‚ฌ-70.78%
2007-1,96ย โ‚ฌ99.09%
2006-0,98ย โ‚ฌ-43.88%
2005-1,75ย โ‚ฌ-82.33%
2004-9,92ย โ‚ฌ-59.23%
2003-24,33ย โ‚ฌ

EPS for similar companies or competitors

Company EPS EPS differencediff. Country
Novartis
NVS
4,69ย โ‚ฌ-73.50%๐Ÿ‡จ๐Ÿ‡ญ Switzerland
Sanofi
SNY
1,70ย โ‚ฌ-90.39%๐Ÿ‡ซ๐Ÿ‡ท France
Regeneron Pharmaceuticals
REGN
37,48ย โ‚ฌ 111.56%๐Ÿ‡บ๐Ÿ‡ธ USA
Sarepta Therapeutics
SRPT
-2,35ย โ‚ฌ-113.28%๐Ÿ‡บ๐Ÿ‡ธ USA
Regulus Therapeutics
RGLS
-0,65ย โ‚ฌ-103.69%๐Ÿ‡บ๐Ÿ‡ธ USA
OPKO Health
OPK
-0,08048ย โ‚ฌ-100.45%๐Ÿ‡บ๐Ÿ‡ธ USA
Teva Pharmaceutical Industries
TEVA
0,56ย โ‚ฌ-96.82%๐Ÿ‡ฎ๐Ÿ‡ฑ Israel
Arrowhead Pharmaceuticals
ARWR
-2,98ย โ‚ฌ-116.81%๐Ÿ‡บ๐Ÿ‡ธ USA